|
1
|
Armitage JO, Gascoyne RD, Lunning MA and
Cavalli F: Non-Hodgkin lymphoma. Lancet. 390:298–310. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qi SN, Li YX, Wang H, Wang WH, Jin J, Song
YW, Wang SL, Liu YP, Zhou LQ and Yu ZH: Diffuse large B-cell
lymphoma: Clinical characterization and prognosis of Waldeyer ring
versus lymph node presentation. Cancer. 115:4980–4989. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu RY, Li YX, Wang WH, Jin J, Wang SL, Liu
YP, Song YW, Fang H, Ren H, Liu QF, et al: Clinical disparity and
favorable prognoses for patients with Waldeyer ring extranodal
nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma. Am
J Clin Oncol. 37:41–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu YG, Qi SN, Wang SL, Liu YP, Wang WH,
Jin J, Song YW, Ren H, Fang H, He XH, et al: Dosimetric and
clinical outcomes with intensity modulated radiation therapy after
chemotherapy for patients with early-stage diffuse large B-cell
lymphoma of Waldeyer ring. Int J Radiat Oncol Biol Phys.
96:379–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Phan J, Mazloom A, Medeiros LJ, Zreik TG,
Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, et
al: Benefit of consolidative radiation therapy in patients with
diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J
Clin Oncol. 28:4170–4176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moser EC, Kluin-Nelemans HC, Carde P,
Meerwaldt JH, Tirelli U, Aleman BM, Baars J, Thomas J, van Glabbeke
M and Noordijk EM: Impact of involved field radiotherapy in partial
response after doxorubicin-based chemotherapy for advanced
aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys.
66:1168–1177. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Horning SJ, Weller E, Kim K, Earle JD,
O'Connell MJ, Habermann TM and Glick JH: Chemotherapy with or
without radiotherapy in limited-stage diffuse aggressive
non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study
1484. J Clin Oncol. 22:3032–3038. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bonnet C, Fillet G, Mounier N, Ganem G,
Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C,
Gisselbrecht C, et al: CHOP alone compared with CHOP plus
radiotherapy for localized aggressive lymphoma in elderly patients:
A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin
Oncol. 25:787–792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Franceschini D, Franzese C, Navarria P,
Ascolese AM, De Rose F, Del Vecchio M, Santoro A and Scorsetti M:
Radiotherapy and immunotherapy: Can this combination change the
prognosis of patients with melanoma brain metastases? Cancer Treat
Rev. 50:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoshimoto Y, Suzuki Y, Mimura K, Ando K,
Oike T, Sato H, Okonogi N, Maruyama T, Izawa S, Noda SE, et al:
Radiotherapy-induced anti-tumor immunity contributes to the
therapeutic efficacy of irradiation and can be augmented by CTLA-4
blockade in a mouse model. PLoS One. 9:e925722014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herrera FG, Bourhis J and Coukos G:
Radiotherapy combination opportunities leveraging immunity for the
next oncology practice. CA Cancer J Clin. 67:65–85. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weichselbaum RR, Liang H, Deng L and Fu
YX: Radiotherapy and immunotherapy: A beneficial liaison? Nat Rev
Clin Oncol. 14:365–379. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Galluzzi L, Kepp O and Kroemer G:
Immunogenic cell death in radiation therapy. Oncoimmunology.
2:e265362013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bloy N, Pol J, Manic G, Vitale I,
Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G and Galluzzi
L: Trial Watch: Radioimmunotherapy for oncological indications.
Oncoimmunology. 3:e9549292014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Surace L, Lysenko V, Fontana AO, Cecconi
V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neefjes
J, et al: Complement is a central mediator of radiotherapy-induced
tumor-specific immunity and clinical response. Immunity.
42:767–777. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kroemer G, Galluzzi L, Kepp O and Zitvogel
L: Immunogenic cell death in cancer therapy. Annu Rev Immunol.
31:51–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ebner DK, Tinganelli W, Helm A, Bisio A,
Yamada S, Kamada T, Shimokawa T and Durante M: The immunoregulatory
potential of particle radiation in cancer therapy. Front Immunol.
8:992017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Demaria S, Golden EB and Formenti SC: Role
of local radiation therapy in cancer immunotherapy. JAMA Oncol.
1:1325–1332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shibutani M, Maeda K, Nagahara H, Iseki Y,
Ikeya T and Hirakawa K: Prognostic significance of the preoperative
lymphocyte-to-monocyte ratio in patients with colorectal cancer.
Oncol Lett. 13:1000–1006. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ji H, Xuan Q, Yan C, Liu T, Nanding A and
Zhang Q: The prognostic and predictive value of the lymphocyte to
monocyte ratio in luminal-type breast cancer patients treated with
CEF chemotherapy. Oncotarget. 7:34881–34889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eo WK, Chang HJ, Kwon SH, Koh SB, Kim YO,
Ji YI, Kim HB, Lee JY, Suh DS, Kim KH, et al: The
lymphocyte-monocyte ratio predicts patient survival and
aggressiveness of ovarian cancer. J Cancer. 7:289–296. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marconato L, Martini V, Stefanello D,
Moretti P, Ferrari R, Comazzi S, Laganga P, Riondato F and Aresu L:
Peripheral blood lymphocyte/monocyte ratio as a useful prognostic
factor in dogs with diffuse large B-cell lymphoma receiving
chemoimmunotherapy. Vet J. 206:226–230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang L, Wang H, Xia ZJ, Huang HQ, Jiang
WQ, Lin TY and Lu Y: Peripheral blood lymphocyte to monocyte ratio
identifies high-risk adult patients with sporadic Burkitt lymphoma.
Ann Hematol. 94:1645–1654. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ji H, Niu X, Yin L, Wang Y, Huang L, Xuan
Q, Li L, Zhang H, Li J, Yang Y, et al: Ratio of immune response to
tumor burden predicts survival via regulating functions of
lymphocytes and monocytes in diffuse large B-cell lymphoma. Cell
Physiol Biochem. 45:951–961. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Campo E, Swerdlow SH, Harris NL, Pileri S,
Stein H and Jaffe ES: The 2008 WHO classification of lymphoid
neoplasms and beyond: Evolving concepts and practical applications.
Blood. 117:5019–5132. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cassidy RJ, Jegadeesh N, Switchenko J,
Danish H, Esiashvili N, Flowers CR and Khan MK: The role of
radiotherapy for patients over age 60 with diffuse large B-cell
lymphoma in the rituximab era. Leuk Lymphoma. 57:1876–1882. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee ST, Liu S, Radvanyi L, Sukhumalchandra
P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G and
Neelapu SS: A novel strategy for rapid and efficient isolation of
human tumor-specific CD4+ and CD8+ T-cell
clones. J Immunol Methods. 331:13–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sharabi AB, Lim M, DeWeese TL and Drake
CG: Radiation and checkpoint blockade immunotherapy:
Radiosensitisation and potential mechanisms of synergy. Lancet
Oncol. 16:e498–e509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou S, Xu L, Ma Y, Tang L, Zhang Y, Shi
Y, Sun L, Chen Y, Liang B, Zhou Y, et al: Peripheral blood
lymphocyte to monocyte ratio recovery from low levels at diagnosis
after completion of first line therapy predicts good clinical
outcomes in patients with diffuse large B-cell lymphoma.
Oncotarget. 8:19556–19565. 2017.PubMed/NCBI
|
|
31
|
Ho CL, Lu CS, Chen JH, Chen YG, Huang TC
and Wu YY: Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio,
and Absolute Lymphocyte Count/Absolute monocyte count prognostic
score in diffuse large B-cell lymphoma: Useful prognostic tools in
the rituximab era. Medicine. 94:e9932015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jia T, Zhang R, Zhu HY, Liang JH, Wang L,
Wu W, Cao L, Li JY and Xu W: Prognostic significance of peripheral
blood absolute monocyte count and lymphocyte to monocyte ratio in
anaplastic large cell lymphoma. Cancer Biomark. Jun 12–2018.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shibutani M, Maeda K, Nagahara H, Ohtani
H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H,
et al: Prognostic significance of the lymphocyte-to-monocyte ratio
in patients with metastatic colorectal cancer. World J
Gastroenterol. 21:9966–9973. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Noy R and Pollard JW: Tumor-associated
macrophages: From mechanisms to therapy. Immunity. 41:49–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin GN, Liu PP, Liu DY, Peng JW, Xiao JJ
and Xia ZJ: Prognostic significance of the pre-chemotherapy
lymphocyte-to-monocyte ratio in patients with previously untreated
metastatic colorectal cancer receiving FOLFOX chemotherapy. Chin J
Cancer. 35:52016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo H, Ge H, Cui Y, Zhang J, Fan R, Zheng
A, Zheng X and Sun Y: Systemic inflammation biomarkers predict
survival in patients of early stage Non-small cell lung cancer
treated with stereotactic ablative radiotherapy-a single center
experience. J Cancer. 9:182–188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dovedi SJ, Lipowska-Bhalla G, Beers SA,
Cheadle EJ, Mu L, Glennie MJ, Illidge TM and Honeychurch J:
Antitumor efficacy of radiation plus immunotherapy depends upon
dendritic cell activation of effector CD8+ T cells.
Cancer Immunol Res. 4:621–630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Golden EB, Chhabra A, Chachoua A, Adams S,
Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg
J, et al: Local radiotherapy and granulocyte-macrophage
colony-stimulating factor to generate abscopal responses in
patients with metastatic solid tumours: A proof-of-principle trial.
Lancet Oncol. 16:795–803. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Postow MA, Callahan MK, Barker CA, Yamada
Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al:
Immunologic correlates of the abscopal effect in a patient with
melanoma. N Engl J Med. 366:925–931. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kumari A and Garnett-Benson C: Effector
function of CTLs is increased by irradiated colorectal tumor cells
that modulate OX-40L and 4-1BBL and is reversed following dual
blockade. BMC Res Notes. 9:922016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
de Winde CM, Elfrink S and van Spriel AB:
Novel insights into membrane targeting of B cell lymphoma. Trends
Cancer. 3:442–453. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jelinek T, Mihalyova J, Kascak M, Duras J
and Hajek R: PD-1/PD-L1 inhibitors in haematological malignancies:
Update 2017. Immunology. 152:357–371. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mitteldorf C, Berisha A, Pfaltz MC,
Broekaert SMC, Schön MP, Kerl K and Kempf W: Tumor microenvironment
and checkpoint molecules in primary cutaneous diffuse large B-cell
lymphoma-new therapeutic targets. Am J Surg Pathol. 41:998–1004.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Boussiotis VA, Chatterjee P and Li L:
Biochemical signaling of pd-1 on T cells and its functional
implications. Cancer J. 20:265–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nemoto Y, Shosu K, Okuda M, Noguchi S and
Mizuno T: Development and characterization of monoclonal antibodies
against canine PD-1 and PD-L1. Vet Immunol Immunopathol. 198:19–25.
2018. View Article : Google Scholar : PubMed/NCBI
|
